Revolution Medicines
RVMD
168 hedge funds and large institutions have $3.11B invested in Revolution Medicines in 2023 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 60 increasing their positions, 39 reducing their positions, and 13 closing their positions.
223% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 13
54% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 39
21% more funds holding
Funds holding: 139 → 168 (+29)
17% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $19.7M
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
4% more capital invested
Capital invested by funds: $2.99B → $3.11B (+$117M)
2.35% less ownership
Funds ownership: 105.32% → 102.97% (-2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$39.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$28.6M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$27.4M |
| 4 |
BlackRock
New York
|
+$18.2M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$67.5M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$48.1M |
| 3 |
CG
Column Group
San Francisco,
California
|
-$39.9M |
| 4 |
State Street
Boston,
Massachusetts
|
-$26M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$18.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Los Angeles Capital Management
Los Angeles,
California
| – | -$311K | -11,614 | Closed |
|
|
VRS
177
Virginia Retirement Systems
Richmond,
Virginia
| – | -$292K | -10,900 | Closed |
|
178
Simplex Trading
Chicago,
Illinois
| – | -$9.73K | -328 | Closed |
|
|
DI
179
Disciplined Investments
Tulsa,
Oklahoma
| – | -$54 | -2 | Closed |
|
|
SFG
180
Steward Financial Group
Colleyville,
Texas
| – | +$771 | +26 | New |
|
RVMD Hedge Fund Activity: Q3 2023 in Review
168 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q3 2023, worth a combined $3.11B — up 3.9% from $2.99B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new RVMD positions and 13 closed out — a net gain of 29 holders — while 60 added to existing stakes and 39 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $39.2M. The largest seller was BVF Inc, cutting an estimated $67.5M.
- 168 institutional investors held Revolution Medicines (RVMD) as of Q3 2023, up from 139 in Q2 2023.
- Funds reported $3.11B of Revolution Medicines stock for Q3 2023, up 3.9% quarter-over-quarter.
- 42 funds opened new Revolution Medicines positions in Q3 2023 and 13 closed out, a net change of +29 holders.
- The largest Revolution Medicines buyer in Q3 2023 was Perceptive Advisors, an estimated $39.2M added.
- The largest Revolution Medicines seller in Q3 2023 was BVF Inc, an estimated $67.5M sold.
Based on aggregated 13F filings for Q3 2023.